Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Common Equity (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Common Equity for 6 consecutive years, with $151.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 483.35% year-over-year to $151.5 million, compared with a TTM value of $151.5 million through Dec 2025, up 483.35%, and an annual FY2025 reading of $151.5 million, up 483.35% over the prior year.
  • Common Equity was $151.5 million for Q4 2025 at SAB Biotherapeutics, down from $165.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $165.1 million in Q3 2025 and bottomed at $12.0 million in Q2 2025.
  • Average Common Equity over 5 years is $46.1 million, with a median of $37.0 million recorded in 2022.
  • Peak annual rise in Common Equity hit 483.35% in 2025, while the deepest fall reached 73.95% in 2025.
  • Year by year, Common Equity stood at $38.5 million in 2021, then dropped by 19.43% to $31.1 million in 2022, then soared by 84.49% to $57.3 million in 2023, then plummeted by 54.68% to $26.0 million in 2024, then skyrocketed by 483.35% to $151.5 million in 2025.
  • Business Quant data shows Common Equity for SABS at $151.5 million in Q4 2025, $165.1 million in Q3 2025, and $12.0 million in Q2 2025.